Citigroup Downgrades Intercept Pharmaceuticals to Neutral, Raises Price Target to $140

Citigroup analyst Joel Beatty downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Buy to Neutral and raises the price target from $85 to $140.

Benzinga · 01/02/2020 11:14

Citigroup analyst Joel Beatty downgrades Intercept Pharmaceuticals (NASDAQ:ICPT) from Buy to Neutral and raises the price target from $85 to $140.